New survival data and emerging treatment strategies are shaping the evolving lung cancer landscape. Dr Gabriel Lenz highlights five key trials from ESMO 2026, examining the latest findings and their potential implications for clinical practice.
New Phase III findings across gastric, gastroesophageal, biliary tract and pancreatic cancers explore the next generation of targeted therapies, immunotherapy combinations and treatment strategies, with important implications for the management of advanced disease.
New survival data and emerging treatment strategies take center stage at ESMO 2026, with seven key studies exploring adjuvant CDK4/6 inhibition, treatment sequencing in advanced disease and the expanding role of antibody–drug conjugates.
From perioperative treatment in high-risk localized disease, to long-term survival in metastatic prostate cancer, here are five key abstracts presented at ESMO 2026 that offer new evidence to consider when evaluating treatment strategies.
New data from VOLGA, KEYNOTE-B15, ENERGIZE, KEYNOTE-866 and POTOMAC examine perioperative treatment combinations, circulating tumor DNA (ctDNA) and bladder-preserving strategies across muscle-invasive and non-muscle-invasive bladder cancer.
New phase 3 results in relapsed or refractory osteosarcoma, updated data for a direct β-catenin inhibitor in desmoid tumors and clinical findings across other rare sarcoma subtypes feature among the key studies presented at ESMO 2026. This round-up examines five abstracts, covering study designs, efficacy outcomes and safety data.
ESMO 2026 brought phase 3 data on an individualized mRNA-based therapy for resected melanoma, a histone deacetylase inhibitor combination for advanced melanoma, and updated survival results for adjuvant cemiplimab in cutaneous squamous cell carcinoma. Dr Rodrigo Munhoz selects the key abstracts shaping the melanoma and skin cancer landscape.
New data from ESMO 2026 explore next-generation bispecific antibodies, antibody–drug conjugates and targeted therapies across multiple myeloma, lymphoma and myeloid malignancies, providing early clinical findings in several areas of unmet need.
Anxiety can change at every stage of the cancer journey, from diagnosis and treatment to surveillance and survivorship. Dr Chirag B Jain discusses why a longitudinal approach to anxiety assessment and management is needed and how personalized supportive care could help address patients’ evolving needs.
Can advances in antibody-drug conjugate design translate into meaningful survival benefits across more tumor types and earlier treatment settings, without unacceptable toxicity? We examine the key trials to watch at ESMO 2026, and the clinical questions they aim to address.
Whether you are joining onsite or via the virtual platform, we have put together a quick guide to the headline sessions: when and where they run, who is presenting, and links to explore each one in the programme planner, so you can decide which to prioritize.
From personalized cancer vaccines and antibody–drug conjugates, to novel immunotherapy combinations, the 12 selected presidential late-breaking abstracts at ESMO 2026 will explore potential advances across multiple tumor types. Here are the key studies to watch and the clinical questions their results could help answer.
